Disc Medicine Q3 net loss narrows to $59.5 million; APOLLO Phase 3 trial met endpoints
Disc Medicine reported a third-quarter 2026 net loss of $59.5 million, down from $62.3 million a year earlier, and said its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints. The company plans to resubmit its New Drug Application to the FDA by the end of 2026, which matters to shareholders because it moves the lead drug toward a possible approval decision in mid-2027.
Key points
- Net loss was $59.5 million for the quarter ended September 30, 2026, compared with $62.3 million a year earlier.
- Research and development expenses were $44.1 million, down from $50.3 million, while SG&A expenses rose to $20.1 million from $17.4 million.
- Bitopertin reduced whole-blood metal-free PPIX by 41.4% versus placebo (p<0.0001) in the APOLLO trial.
- Cash, cash equivalents, and marketable securities were $682.8 million at September 30, 2026, plus net proceeds of about $485.9 million from an October 2026 public offering.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.